Taken together, these results suggest that high-dose regimens of TNO155 or lorlatinib alone might be sufficient to delay tumor growth of ALK mutated tumors; however, low-dose combination treatments could impact tumor responses more significantly due to their ability to treat for longer periods with fewer toxicities. The gene discussed is ALK; the disease is neoplasm.